Document Detail

Relaxin: a new approach for the treatment of acute congestive heart failure.
MedLine Citation:
PMID:  20926940     Owner:  NLM     Status:  In-Process    
Relaxin, a naturally-occurring hormone in the insulin family, was discovered to have a physiologic role in pregnancy. Named initially for its relaxing effect on the pubic ligament, relaxin receptors have since been found to be widely distributed in many organs in both males and females. Acting through multiple pathways, including the stimulation of gelatinases leading to activation of endothelin type B receptors and subsequently nitric oxide, relaxin has been shown to cause vasodilation. In animal models and studies in humans, relaxin has been shown to increase cardiac output and renal perfusion. Due to these effects, relaxin has been examined as a treatment for acute heart failure. The results of phase I and II trials have shown favorable clinical trends without any major adverse events, suggesting that relaxin has the potential to be an effective medication for acute heart failure in conjunction with or in place of current treatments.
Jason Grossman; William H Frishman
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cardiology in review     Volume:  18     ISSN:  1538-4683     ISO Abbreviation:  Cardiol Rev     Publication Date:    2010 Nov-Dec
Date Detail:
Created Date:  2010-10-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9304686     Medline TA:  Cardiol Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  305-12     Citation Subset:  IM    
Department of Internal Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular di...
Next Document:  Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan.